nach oben

Endocrine

Erschienen in:

04.05.2021 | Research Letter

Usefulness of ¹²³I-spect/ct to assess the response to initial therapy in differentiated thyroid cancer patients

verfasst von: Alfredo Campennì, Alexis Vrachimis, Massimiliano Siracusa, Sergio Baldari, Luca Giovanella

Erschienen in: Endocrine | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

The response to initial therapy of differentiated thyroid cancer (DTC) is recommended to be evaluated 6–12 months after treatment via basal and/or stimulated-thyroglobulin (Tg) measurements and neck ultrasonography (nUS) [1]. Furthermore, diagnostic radioiodine whole body scintigraphy (Dx-WBS) is recommended only in selected cases [i.e., high risk DTC; positive anti-thyroglobulin antibody (TgAb), etc.] [1]. However, nUS is operator-dependent, limited in exploring the central cervical area and inherently unable to provide information concerning distant spread [2]. Accordingly, in case of undetected recurrences, an increased Tg level compounded with falsely negative nUS will be erroneously rated as intermediate or incomplete biochemical response with attached consequences in patients’ management. …

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid: Off. J. Am. Thyroid Assoc. (2016). https://doi.org/10.1089/thy.2015.0020

L. Lamartina, D. Deandreis, C. Durante, S. Filetti, ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur. J. Endocrinol. (2016). https://doi.org/10.1530/EJE-16-0088

A. Campennì, L. Giovanella, M. Siracusa, A. Alibrandi, S.A. Pignata, S. Giovinazzo, F. Trimarchi, R.M. Ruggeri, S. Baldari, (99m)Tc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology. Thyroid: Off. J. Am. Thyroid Assoc. (2016). https://doi.org/10.1089/thy.2016.0135

A. Campennì, L. Giovanella, S.A. Pignata, A. Vento, A. Alibrandi, L. Sturiale, R. Laudicella, A.D. Comis, R. Filice, G. Giuffrida, M.E. Stipo, S. Giovinazzo, F. Trimarchi, R.M. Ruggeri, S. Baldari, Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. Oncotarget (2018). https://doi.org/10.18632/oncotarget.24766

A. Campennì, D. Barbaro, M. Guzzo, F. Capoccetti, L. Giovanella, Personalized management of differentiated thyroid cancer in real life—practical guidance from a multidisciplinary panel of experts. Endocrine (2020). https://doi.org/10.1007/s12020-020-02418-x

A. Campennì, R.M. Ruggeri, M. Siracusa, A.D. Comis, D. Romano, A. Vento, H. Lanzafame, F. Capoccetti, A. Alibrandi, S. Baldari, L. Giovanella, Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients. Eur. J. Nuclear Med. Mol. Imaging (2021). https://doi.org/10.1007/s00259-020-05153-7

R.M. Tuttle, S. Ahuja, A.M. Avram, V.J. Bernet, P. Bourguet, G.H. Daniels, G. Dillehay, C. Draganescu, G. Flux, D. Führer, L. Giovanella, B. Greenspan, M. Luster, K. Muylle, J. Smit, D. Van Nostrand, F.A. Verburg, L. Hegedüs, Controversies, Consensus, and Collaboration in the Use of ¹³¹I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid: Off. J. Am. Thyroid Assoc. (2019). https://doi.org/10.1089/thy.2018.0597

L. Giovanella, L.H. Duntas, Management of endocrine disease: the role of rhTSH in the management of differentiated thyroid cancer: pros and cons. Eur. J. Endocrinol. (2019). https://doi.org/10.1530/EJE-19-0149

F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. (2006). https://doi.org/10.1530/eje.1.02158

10.

D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L.Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: Off. J. Am. Thyroid Assoc. (2009). https://doi.org/10.1089/thy.2009.0110

11.

JC. Sisson, A.M. Avram, S.A. Lawson, P.G. Gauger, G. M. Doherty, The so-called stunning of thyroid tissue. J Nucl Med. 47(9),1406–12 (2006). PMID: 16954546

12.

C. Pirich, G. Schweighofer-Zwink, Less is more: reconsidering the need for regular use of diagnostic whole body radioiodine scintigraphy in the follow-up of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imag. (2017). https://doi.org/10.1007/s00259-017-3632-5

13.

M. Dietlein, J. Dressler, W. Eschner, F. Grünwald, M. Lassmann, B. Leisner, M. Luster, C. Reiners, H. Schicha, O. Schober, Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nucl. Med. 46(5), 206–212 (2007)

14.

J.M. Gonzalez Carvalho, D. Görlich, O. Schober, C. Wenning., B. Riemann, F.A. Verburg, A. Vrachimis, Evaluation of ¹³¹I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients. Eur. J. Nucl. Med. Mol. Imaging (2017). https://doi.org/10.1007/s00259-016-3581-4

15.

T. Barwick, I. Murray, H. Megadmi, W.M. Drake, P.N. Plowman, S.A. Akker, S.L. Chew, A.B. Grossman, N. Avril, Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur. J. Endocrinol. (2010). https://doi.org/10.1530/EJE-09-1023

16.

A. Spanu, M.E. Solinas, F. Chessa, D. Sanna, S. Nuvoli, G. Madeddu, 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J. Nucl. Med. (2009) https://doi.org/10.2967/jnumed.108.056572

17.

A.S. Alzahrani, O. AlShaikh, M. Tuli, A. Al-Sugair, R. Alamawi, M.M. Al-Rasheed, Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer. Clin. Nucl. Med. (2012). https://doi.org/10.1097/RLU.0b013e31823ea463

18.

A. Siddiqi, R.R. Foley, K.E. Britton, A. Sibtain, P.N. Plowman, A.B. Grossman, J.P. Monson, G.M. Besser, The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin. Endocrinol. (2001). https://doi.org/10.1046/j.1365-2265.2001.01376.x

Titel: Usefulness of 123I-spect/ct to assess the response to initial therapy in differentiated thyroid cancer patients
verfasst von: Alfredo Campennì
Alexis Vrachimis
Massimiliano Siracusa
Sergio Baldari
Luca Giovanella
Publikationsdatum: 04.05.2021
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02737-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Usefulness of ¹²³I-spect/ct to assess the response to initial therapy in differentiated thyroid cancer patients

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Thyroid hormone deiodinases response in brain of spontaneausly hypertensive rats after hypotensive effects induced by mandibular extension

The association between vitamin D3 and diabetes in both hyperuricemia and non-hyperuricemia populations

Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases

Polymorphism in BACH2 gene is a marker of polyglandular autoimmunity

Nonfunctional adrenal adenomas and impaired glucose metabolism: a systematic review and meta-analysis

Insulinoma-associated protein 1(INSM1) is a superior marker for the diagnosis of gastroenteropancreatic neuroendoerine neoplasms: a meta-analysis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin